WallStreetZen

NYSE: ZTS
Zoetis Inc Earnings & Revenue

ZTS past earnings growth

How has ZTS's earnings growth performed historically?
Company
9.55%
Industry
5.25%
Market
38.16%
ZTS's earnings have grown faster (38.3% per year) than the US Drug Manufacturers - Specialty & Generic industry average (-4.75%)
Performance
ZTS's earnings have grown faster (38.3% per year) than the US market average (19.7%)
Performance
ZTS's earnings growth is slowing down - its growth over the last year (9.55%) is below its 5-year compound annual rate (38.3%)
Performance

ZTS past revenue growth

How has ZTS's revenue growth performed historically?
Company
6.63%
Industry
31.28%
Market
20.21%
ZTS's revenue has grown slower (6.97% per year) than the US Drug Manufacturers - Specialty & Generic industry average (50.21%)
Performance
ZTS's revenue has grown slower (6.97% per year) than the US market average (18.53%)
Performance
ZTS's revenue growth is slowing down - its growth over the last year (6.63%) is below its 5-year compound annual rate (6.97%)
Performance

ZTS earnings and revenue history

Current Revenue
$6.7B
Current Earnings
$1.6B
Current Profit Margin
24.5%
ZTS's has demonstrated consistent long-term earnings growth over the past 10 years (1,463.64%)
Performance

ZTS Return on equity

Current Company
50%
Current Industry
1.9%
Current Market
49.8%
ZTS's Return on Equity (50%) shows a company that is highly efficient at transforming shareholder equity into returns
Performance

ZTS Return on assets

Current Company
12.6%
Current Industry
1.2%
Current Market
5.4%
ZTS is generating higher Return on Assets (12.6%) than the US Drug Manufacturers - Specialty & Generic industry average (-0.02%)
Performance

ZTS Return on capital employed

Current Company
19.49%
Current Industry
4.7%
ZTS's ability to generate Return on Capital (19.49%) has decreased compared to 3 years ago (22.72%)
Performance

ZTS earnings dates

Next earnings date
May 4, 2021

Zoetis Earnings & Revenue FAQ

What were ZTS's earnings last quarter?

On Feb 16, 2021, Zoetis (NYSE: ZTS) reported Q4 2020 earnings per share (EPS) of $0.75, up 7.41% year over year. Total Zoetis earnings for the quarter were $359.00 million. In the same quarter last year, Zoetis's earnings per share (EPS) was $0.81.

What was ZTS's earnings growth in the past year?

As of Q2 2021, Zoetis's earnings has grown 9.55% year over year. This is 4.31 percentage points higher than the US Drug Manufacturers - Specialty & Generic industry earnings growth rate of 5.25%. Zoetis's earnings in the past year totalled $1.64 billion.

What is ZTS's earnings date?

Zoetis's earnings date is May 04, 2021. Add ZTS to your watchlist to be reminded of ZTS's next earnings announcement.

What was ZTS's revenue last quarter?

On Feb 16, 2021, Zoetis (NYSE: ZTS) reported Q4 2020 revenue of $1.81 billion up 7.95% year over year. In the same quarter last year, Zoetis's revenue was $1.67 billion.

What was ZTS's revenue growth in the past year?

As of Q2 2021, Zoetis's revenue has grown 6.63% year over year. This is 24.65 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry revenue growth rate of 31.28%. Zoetis's revenue in the past year totalled $6.68 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.